問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Search Result

Search Result

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

吳韋璁

Recruiting

List

50Cases

2019-05-02 - 2026-01-17

Phase III

A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate the Impact of Evolocumab on Major Cardiovascular Events in Patients at High Cardiovascular Risk Without Prior Myocardial Infarction or Stroke

  • Condition/Disease

    Coronary Heart Disease (CHD)

  • Test Drug

    Repatha

Participate Sites
10Sites

Recruiting9Sites

Terminated1Sites

2023-04-13 - 2027-05-05

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
13Sites

Recruiting13Sites

2023-03-01 - 2027-02-28

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
17Sites

Recruiting17Sites

2023-01-30 - 2024-12-29

Phase II

A Phase 2 Randomized, Placebo-controlled, Double-blind, Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity, With or Without Type 2 Diabetes Mellitus

  • Condition/Disease

    Type 2 Diabetes Mellitus、Obesity、Overweight

  • Test Drug

    AMG133

Participate Sites
4Sites

Recruiting4Sites

2021-05-18 - 2023-12-31

Phase II

A Phase 2b, Randomised, Double-Blind, Active-Controlled, Multi-Centre Study to Evaluate the Efficacy, Safety and Tolerability of Oral AZD9977 and Dapagliflozin Treatment in Patients with Heart Failure and Chronic Kidney Disease

  • Condition/Disease

    Heart Failure

  • Test Drug

    AZD9977及Dapagliflozin

Participate Sites
10Sites

Not yet recruiting5Sites

Recruiting5Sites

2023-07-03 - 2028-07-26

Phase III

A Phase 3, Randomized, Double-Blind Study to Investigate the Efficacy and Safety of Once-Daily Oral LY3502970 Compared With Placebo in Adult Participants With Obesity or Overweight With Weight-Related Comorbidities (ATTAIN-1)

  • Condition/Disease

    Obesity 、Overweight、 Overweight or Obesity

  • Test Drug

    LY3502970

Participate Sites
5Sites

Recruiting5Sites

2022-01-19 - 2027-10-20

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Not yet recruiting2Sites

Recruiting7Sites

2022-12-05 - 2024-09-30

Phase III

A Multicenter, International, Randomized, Placebo Controlled, Double-blind, Parallel Group and Event Driven Phase 3 Study of the Oral FXIa Inhibitor Asundexian (BAY 2433334) for the Prevention of Ischemic Stroke in Male and Female Participants Aged 18 Years and Older After an Acute Non-cardioembolic Ischemic Stroke or High-risk TIA

  • Condition/Disease

    Prevention of Ischemic Stroke 、Acute Non-cardioembolic Ischemic Stroke、 High-risk Transient Ischemic Attack

  • Test Drug

    AsundexianPlacebo (for Asundexian)ApixabanPlacebo (for Apixaban)

Participate Sites
23Sites

Not yet recruiting2Sites

Recruiting20Sites

Terminated1Sites

2020-03-17 - 2024-05-02

Phase III

A multicenter, randomized, double-blind, parallelgroup, placebo-controlled study to evaluate the efficacy and safety of finerenone on morbidity and mortality in participants with heart failure (NYHA II-IV) and left ventricular ejection fraction >= 40%. (LVEF >= 40%)

  • Condition/Disease

    heart failure

  • Test Drug

    Finerenone/ BAY 94-8862

Participate Sites
8Sites

Not yet recruiting2Sites

Recruiting6Sites

2021-09-01 - 2022-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting10Sites

Terminated2Sites

1 2 3 4 5
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB